AlphAIAlphAI — Financial news for AI agents
investing.comOCT 142 min read$VNDA

Vanda’s phase III trial for social anxiety drug fails

Vanda Pharmaceuticals (VNDA) reported that its phase III trial for VQW-765, a drug for social anxiety, failed to meet primary and secondary endpoints. The study showed no significant difference in distress levels between the drug and placebo. The company has paused the program pending further analysis. The drug was safe and well-tolerated, according to the company.

Original reporting
investing.com
Published Oct 14, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$VNDA
Bearish
high confidence
Mentioned
$VNDA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$VNDABearishMed
01

Why it matters

The failure erases near‑term revenue expectations from the program and may affect the company's cash runway and valuation.

02

Market read

The announcement contributed to a broader tech market decline as investors priced in heightened risk for biotech trial outcomes.

03

What to watch

Potential for a future NDA filing if additional data supports efficacy; partnership with Novartis could mitigate downside.

Relevance 8/10Novelty 9/10Timing: today

Background

Vanda Pharmaceuticals disclosed its Phase III results for VQW-765, a nicotinic receptor partial agonist licensed from Novartis, targeting social anxiety disorder.

Company-level read

Ticker impact

$VNDABearishHigh confidence
Context

Phase III trial of VQW-765 for social anxiety failed to meet primary and key secondary endpoints, announced today.

Expected impact

likely pressure as the market prices in the failed trial data

Evidence & confidence

First disclosure of a pivotal Phase III failure for a listed biotech; investors typically react sharply to such news.

Market effects

Sector

May dampen sentiment for anxiety‑disorder therapeutics and broader biotech trial pipelines.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond biotech sector.

Counterpoint

What could challenge this read

If the company can pivot the asset to a different indication, the drop may be overstated.

Key entities

  • company
    Vanda Pharmaceuticals Inc.

    US‑listed biotech developing VQW-765 for social anxiety.

  • company
    Novartis

    Original licensor of the VQW-765 molecule.

Read at source← All news

StoryVanda Pharmaceuticals reports Phase III failure of VQW‑765 for social anxiety disorder

Related articles

OCT 14
$VNDAHighAI 8/10

Vanda Pharmaceuticals stock falls after anxiety drug trial fails

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after its anxiety drug VQW-765 failed to meet the primary endpoint in a Phase III trial. The study did not show statistical significance in reducing distress levels in female participants with social anxiety disorder. The company plans to analyze the full dataset before deciding on next steps. VQW-765 was licensed from Novartis and is being developed for psychiatric disorders.

investing.com2 min
OCT 14
$VNDAMedAI 8/10

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Vanda Pharmaceuticals (VNDA) reported that its Phase III study of VQW-765 for social anxiety disorder did not meet the primary endpoint, failing to show a significant difference from placebo. The study evaluated 546 adults and did not confirm earlier Phase II results. The company plans to analyze the full dataset before deciding next steps. VQW-765 is a novel alpha 7 nicotinic acetylcholine receptor partial agonist.

prnewswire.com2 min
OCT 5
$VNDAMedAI 8/10

Wainwright reiterates Buy on Vanda stock after sleep disorder trial

H.C. Wainwright reiterated a Buy rating and $20 price target for Vanda Pharmaceuticals (VNDA) after positive Phase 3 trial results for its sleep disorder treatment. The stock is down over 10% in the past week, trading at $4.63. The study met its primary endpoint, with HETLIOZ shifting sleep onset 42.5 minutes earlier vs. placebo. Vanda reported a disappointing Q2 2026, missing earnings and revenue estimates, with an adjusted loss of $1.04 per share and revenue of $50.5 million.

investing.com2 min
SEP 30
$VNDAHighAI 8/10

Vanda Reports Positive Phase 3 Results For HETLIOZ In Delayed Sleep-Wake Phase Disorder; Stock Up

Vanda Pharmaceuticals (VNDA) reported positive Phase 3 results for HETLIOZ in treating Delayed Sleep-Wake Phase Disorder, meeting primary endpoints. HETLIOZ shifted sleep onset 37.1 minutes earlier vs. placebo. The company plans to discuss results with the FDA and submit an sNDA. HETLIOZ sales declined 66% YoY in Q2 2026, partly due to shipment timing. VNDA stock is up 10.14% in overnight trading.

rttnews.com2 min
SEP 29
$VNDAHighAI 9/10

Why is Vanda Pharmaceuticals stock surging today?

Vanda Pharmaceuticals (VNDA) stock rose 12% in after-hours trading to $5.63 after reporting positive phase III results for its Hetlioz treatment in delayed sleep-wake phase disorder. The trial met its primary endpoint, and the company plans to discuss the data with the FDA. If approved, Hetlioz would be the first FDA-approved medicine for this condition.

investing.com2 min